Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
18 hedge funds and large institutions have $97.3K invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
13% more funds holding
Funds holding: 16 → 18 (+2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
57% less capital invested
Capital invested by funds: $224K → $97.3K (-$127K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$50.6K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$22.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$17.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$9.74K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.88K |
| 2 |
Millennium Management
New York
|
-$521 |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$335 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$5 |
| 5 |
Morgan Stanley
New York
|
-$2 |
FRTX Hedge Fund Activity: Q1 2023 in Review
18 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q1 2023, worth a combined $97.3K — down 57% from $224K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FRTX positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $50.6K. The largest seller was Vanguard Group, cutting an estimated $7.88K.
- 18 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q1 2023, up from 16 in Q4 2022.
- Funds reported $97.3K of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q1 2023, down 57% quarter-over-quarter.
- 4 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q1 2023 and 1 closed out, a net change of +3 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q1 2023 was Virtu Financial, an estimated $50.6K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q1 2023 was Vanguard Group, an estimated $7.88K sold.
Based on aggregated 13F filings for Q1 2023.